Hypoparathyroidism Clinical Trial
Official title:
Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
To provide palopegteriparatide (TransCon PTH), an investigational parathyroid hormone (PTH) replacement therapy in an expanded access setting for adult patients with hypoparathyroidism who have previously received PTH-treatment, who meet the eligibility criteria for this protocol as described below and have a clear unmet medical need that cannot be adequately treated by a commercial product or a clinical trial.
This is an expanded access program for eligible participants who previously received PTH treatment and who are ineligible for an ongoing TransCon PTH clinical trial. The treating physician/investigator contacts Ascendis Pharma when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program. Participants will start with a fixed dose of study drug and will be individually and progressively titrated to an optimal dose based on serum calcium levels, followed by an individualized dosing period until palopegteriparatide is commercially available to the participant. For patients taking conventional therapy with calcium and or active forms of vitamin D, these therapies will be reduced in dose and/or discontinued during titration of palopegteriparatide. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03364738 -
Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism
|
Phase 3 | |
Active, not recruiting |
NCT00856401 -
ADD-ON Study to Existing Hypoparathyroidism Studies
|
Phase 3 | |
Completed |
NCT05043584 -
Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions
|
N/A | |
Completed |
NCT03728959 -
Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.
|
N/A | |
Not yet recruiting |
NCT06445036 -
Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism.
|
||
Recruiting |
NCT05556629 -
A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA
|
||
Terminated |
NCT00395538 -
Effects of PTH Replacement on Bone in Hypoparathyroidism
|
Phase 3 | |
Completed |
NCT02910466 -
A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
|
Phase 4 | |
Completed |
NCT00001304 -
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
|
Phase 2 | |
Completed |
NCT04569604 -
QoL and Cognitive Function in Patients With Hypoparathyroidism
|
||
Completed |
NCT06449729 -
Endocrine Determinants of Renal Function in Patients With Hypoparathyroidism
|
||
Completed |
NCT03747029 -
Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
|
||
Completed |
NCT05684029 -
Near-Infrared Autofluorescence With PTH Test Strip as an SOP of Parathyroid in Thyroid Surgery
|
||
Not yet recruiting |
NCT06419270 -
Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
|
||
Completed |
NCT00473265 -
Bone Properties in Hypoparathyroidism: Effects of PTH
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05328076 -
Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography
|
||
Completed |
NCT03150108 -
Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT04059380 -
Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY)
|
||
Active, not recruiting |
NCT05965167 -
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
|
Phase 1/Phase 2 | |
Recruiting |
NCT02986607 -
Corticosteroid Rhythms in Hypoparathyroid Patients
|
Early Phase 1 |